Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study

Frederick J Meyers, B. Blumenstein, E. D. Crawford, H. E. Hynes, J. E. Montie, S. A. Taylor, H. B. Grossman, R. B. Natale

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The combination of cisplatin and dichloromethotrexate is a pharmacologically rational strategy designed to avoid the nephrotoxicity associated with the systemic chemotherapy of bladder cancer. Of 97 patients with metastatic bladder cancer entered into this study 73 with good renal function received cisplatin and dichloromethotrexate, while 24 with impaired renal function received dichloromethotrexate alone. No responses were noted in the latter group. A 42% response rate (95% exact confidence interval 30.0 to 55.2%), including 9 patients (14%) who achieved a complete response, was observed in the combination group. The toxicity patterns in both groups of patients were consistent with the hypothesis that renal toxicity would be ameliorated with the use of the methotrexate analogue. However, the failure to achieve a higher overall response rate despite near maximum tolerated doses of dichloromethotrexate discourages future studies with this agent. New agents for metastatic bladder cancer should be tested as first line therapy.

Original languageEnglish (US)
Pages (from-to)52-54
Number of pages3
JournalJournal of Urology
Volume148
Issue number1
StatePublished - 1992
Externally publishedYes

Keywords

  • bladder neoplasms
  • carcinoma, transitional cell
  • cisplatin
  • methotrexate

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this

    Meyers, F. J., Blumenstein, B., Crawford, E. D., Hynes, H. E., Montie, J. E., Taylor, S. A., Grossman, H. B., & Natale, R. B. (1992). Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. Journal of Urology, 148(1), 52-54.